Search

Your search keyword '"Dilhuydy, Marie Sarah"' showing total 440 results
Start Over Author "Dilhuydy, Marie Sarah"
440 results on '"Dilhuydy, Marie Sarah"'

1. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

Author

Dartigeas, Caroline, Quinquenel, Anne, Ysebaert, Loïc, Dilhuydy, Marie-Sarah, Anglaret, Bruno, Slama, Borhane, Le Du, Katell, Tardy, Stéphanie, Tchernonog, Emmanuelle, Orfeuvre, Hubert, Voillat, Laurent, Guidez, Stéphanie, Malfuson, Jean-Valère, Dupuis, Sandrine, Deslandes, Marine, Feugier, Pierre, and Leblond, Véronique

Published
2024
Full Text
View/download PDF

2. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Author

Michallet, Anne-Sophie, Letestu, Rémi, Le Garff-Tavernier, Magali, Campos, Lydia, Ticchioni, Michel, Dilhuydy, Marie-Sarah, Morisset, Stephane, Rouille, Valérie, Mahé, Béatrice, Laribi, Kamel, Villemagne, Bruno, Ferrant, Emmanuelle, Tournilhac, Olivier, Delmer, Alain, Molina, Lysiane, Leblond, Véronique, Tomowiak, Cécile, de Guibert, Sophie, Orsini-Piocelle, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc Mathieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan-Graczyk, Margot, Vilque, Jean-Pierre, Schleinitz, Thérèse Aurran, Cymbalista, Florence, Leprêtre, Stéphane, Lévy, Vincent, Nguyen-Khac, Florence, and Feugier, Pierre

Published
2023
Full Text
View/download PDF

3. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

Author

Brown, Jennifer R, Moslehi, Javid, Ewer, Michael S, O'Brien, Susan M, Ghia, Paolo, Cymbalista, Florence, Shanafelt, Tait D, Fraser, Graeme, Rule, Simon, Coutre, Steven E, Dilhuydy, Marie‐Sarah, Cramer, Paula, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C, Treon, Steven, Liu, Emily Y, Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay, Mahler, Michelle, Yang, Huiying, Graef, Thorsten, and Burger, Jan A

Subjects
Cancer, Clinical Research, Clinical Trials and Supportive Activities, Hematology, Rare Diseases, Good Health and Well Being, Adenine, Aged, Female, Hematologic Neoplasms, Hemorrhage, Humans, Incidence, Male, Middle Aged, Piperidines, Pyrazoles, Pyrimidines, Randomized Controlled Trials as Topic, Risk Factors, Time Factors, B-cell neoplasms, lymphoid leukaemias, signalling therapies, clinical results in lymphomas, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B-cell malignancies. In ibrutinib clinical studies, low-grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We analysed the incidence of and risk factors for MH from 15 ibrutinib clinical studies (N = 1768), including 4 randomised controlled trials (RCTs). Rates of any-grade bleeding were similar for single-agent ibrutinib and ibrutinib combinations (39% and 40%). Low-grade bleeding was more common in ibrutinib-treated than comparator-treated patients (35% and 15%), and early low-grade bleeding was not associated with MH. The proportion of MH in RCTs was higher with ibrutinib than comparators (4.4% vs. 2.8%), but after adjusting for longer exposure with ibrutinib (median 13 months vs. 6 months), the incidence of MH was similar (3.2 vs. 3.1 per 1000 person-months). MH led to treatment discontinuation in 1% of all ibrutinib-treated patients. Use of anticoagulants and/or antiplatelets (AC/AP) during the study was common (~50% of patients) and had an increased exposure-adjusted relative risk for MH in both the total ibrutinib-treated population (1.9; 95% confidence interval, 1.2-3.0) and RCT comparator-treated patients (2.4; 95% confidence interval, 1.0-5.6), indicating that ibrutinib may not alter the effect of AC/AP on the risk of MH in B-cell malignancies.

Published
2019

4. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Author

Brown, Jennifer R, Moslehi, Javid, O’Brien, Susan, Ghia, Paolo, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D, Fraser, Graeme, Rule, Simon, Kipps, Thomas J, Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C, Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F, Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle, and Burger, Jan A

Subjects
Orphan Drug, Clinical Trials and Supportive Activities, Aging, Rare Diseases, Hematology, Lymphoma, Heart Disease, Cancer, Cardiovascular, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adenine, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Atrial Fibrillation, Disease Management, Female, Follow-Up Studies, Hemorrhage, Humans, Incidence, Male, Middle Aged, Piperidines, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines, Randomized Controlled Trials as Topic, Risk Factors, Time Factors, Immunology
Abstract

The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6-16% of ibrutinib patients. We pooled data from 1505 chronic lymphocytic leukemia and mantle cell lymphoma patients enrolled in four large, randomized, controlled studies to characterize AF with ibrutinib and its management. AF incidence was 6.5% [95% Confidence Interval (CI): 4.8, 8.5] for ibrutinib at 16.6-months versus 1.6% (95%CI: 0.8, 2.8) for comparator and 10.4% (95%CI: 8.4, 12.9) at the 36-month follow up; estimated cumulative incidence: 13.8% (95%CI: 11.2, 16.8). Ibrutinib treatment, prior history of AF and age 65 years or over were independent risk factors for AF. Multiple AF events were more common with ibrutinib (44.9%; comparator, 16.7%) among patients with AF. Most (85.7%) patients with AF did not discontinue ibrutinib, and more than half received common anticoagulant/antiplatelet medications on study. Low-grade bleeds were more frequent with ibrutinib, but serious bleeds were uncommon (ibrutinib, 2.9%; comparator, 2.0%). Although the AF rate among older non-trial patients with comorbidities is likely underestimated by this dataset, these results suggest that AF among clinical trial patients is generally manageable without ibrutinib discontinuation (clinicaltrials.gov identifier: 01578707, 01722487, 01611090, 01646021).

Published
2017

5. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort

Author

Bouclet, Florian, Calleja, Anne, Dilhuydy, Marie-Sarah, Véronèse, Lauren, Pereira, Bruno, Amorim, Sandy, Cymbalista, Florence, Herbaux, Charles, de Guibert, Sophie, Roos-Weil, Damien, Hivert, Bénédicte, Aurran, Thérèse, Dupuis, Jehan, Blouet, Anaise, Tchernonog, Emmanuelle, Laribi, Kamel, Dmytruck, Nataliya, Morel, Pierre, Michallet, Anne-Sophie, Dartigeas, Caroline, Tournilhac, Olivier, Nguyen-Khac, Florence, Delmer, Alain, Feugier, Pierre, Ysebaert, Loïc, and Guièze, Romain

Published
2021
Full Text
View/download PDF

6. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

Author

DARTIGEAS, Caroline, primary, QUINQUENEL, Anne, additional, YSEBAERT, Loïc, additional, DILHUYDY, Marie-Sarah, additional, ANGLARET, Bruno, additional, SLAMA, Borhane, additional, DU, Katell LE, additional, TARDY, Stéphanie, additional, TCHERNONOG, Emmanuelle, additional, ORFEUVRE, Hubert, additional, VOILLAT, Laurent, additional, GUIDEZ, Stéphanie, additional, MALFUSON, Jean-Valère, additional, DUPUIS, Sandrine, additional, DESLANDES, Marine, additional, FEUGIER, Pierre, additional, and LEBLOND, Véronique, additional

Published
2024
Full Text
View/download PDF

7. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Author

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O’Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F., and Hallek, Michael

Published
2019
Full Text
View/download PDF

8. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

Author

Michallet, Anne-Sophie, Dilhuydy, Marie-Sarah, Subtil, Fabien, Rouille, Valerie, Mahe, Beatrice, Laribi, Kamel, Villemagne, Bruno, Salles, Gilles, Tournilhac, Olivier, Delmer, Alain, Portois, Christelle, Pegourie, Brigitte, Leblond, Veronique, Tomowiak, Cecile, de Guibert, Sophie, Orsini, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc Mathieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan Graczyk, Malgorzata, Vilque, Jean P, Aurran, Thérèse, Cymbalista, Florence, Lepretre, Stéphane, Lévy, Vincent, Nguyen-Khac, Florence, Le Garff-Tavernier, Magali, Aanei, Carmen, Ticchioni, Michel, Letestu, Rémi, and Feugier, Pierre

Published
2019
Full Text
View/download PDF

9. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma

Author

O'Brien, Susan, Hillmen, Peter, Coutre, Steven, Barr, Paul M., Fraser, Graeme, Tedeschi, Alessandra, Burger, Jan A., Dilhuydy, Marie-Sarah, Hess, Georg, Moreno, Carol, Cramer, Paula, Liu, Emily, Chang, Stephen, Vermeulen, Jessica, Styles, Lori, Howes, Angela, James, Danelle F., Patel, Kalpesh, Graef, Thorsten, and Valentino, Rudolph

Published
2018
Full Text
View/download PDF

10. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study

Author

Dartigeas, Caroline, Van Den Neste, Eric, Léger, Julie, Maisonneuve, Hervé, Berthou, Christian, Dilhuydy, Marie-Sarah, De Guibert, Sophie, Leprêtre, Stéphane, Béné, Marie C, Nguyen-Khac, Florence, Letestu, Rémi, Cymbalista, Florence, Rodon, Philippe, Aurran-Schleinitz, Thérèse, Vilque, Jean-Pierre, Tournilhac, Olivier, Mahé, Béatrice, Laribi, Kamel, Michallet, Anne-Sophie, Delmer, Alain, Feugier, Pierre, Lévy, Vincent, Delépine, Roselyne, Colombat, Philippe, and Leblond, Véronique

Published
2018
Full Text
View/download PDF

12. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Author

Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian, Pristupa, Aleksander, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L, Dilhuydy, Marie-Sarah, Pylypenko, Halyna, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Villa, Diego, Samoilova, Olga, Panagiotidis, Panagiots, Goy, Andre, Mato, Anthony, Pavlovsky, Miguel A, Karlsson, Claes, Mahler, Michelle, Salman, Mariya, Sun, Steven, Phelps, Charles, Balasubramanian, Sriram, Howes, Angela, and Hallek, Michael

Published
2016
Full Text
View/download PDF

13. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Author

Lavezzi, Silvia Maria, de Jong, Jan, Neyens, Martine, Cramer, Paula, Demirkan, Fatih, Fraser, Graeme, Bartlett, Nancy, Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Goy, Andre, Ganguly, Siddhartha, Salman, Mariya, Howes, Angela, Mahler, Michelle, De Nicolao, Giuseppe, and Poggesi, Italo

Published
2019
Full Text
View/download PDF

15. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

Author

Guièze, Romain, Robbe, Pauline, Clifford, Ruth, de Guibert, Sophie, Pereira, Bruno, Timbs, Adele, Dilhuydy, Marie-Sarah, Cabes, Maite, Ysebaert, Loïc, Burns, Adam, Nguyen-Khac, Florence, Davi, Frédéric, Véronèse, Lauren, Combes, Patricia, Le Garff-Tavernier, Magali, Leblond, Véronique, Merle-Béral, Hélène, Alsolami, Reem, Hamblin, Angela, Mason, Joanne, Pettitt, Andrew, Hillmen, Peter, Taylor, Jenny, Knight, SamanthaJ.L., Tournilhac, Olivier, and Schuh, Anna

Published
2015
Full Text
View/download PDF

16. Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors

Author

Calmettes, Claire, Vigouroux, Stéphane, Labopin, Myriam, Tabrizi, Reza, Turlure, Pascal, Lafarge, Xavier, Marit, Gérald, Pigneux, Arnaud, Leguay, Thibaut, Bouabdallah, Krimo, Dilhuydy, Marie-Sarah, Duclos, Cédric, Mohr, Catherine, Lascaux, Axelle, Dumas, Pierre-Yves, Dimicoli-Salazar, Sophie, Saint-Lézer, Arnaud, and Milpied, Noël

Published
2015
Full Text
View/download PDF

17. A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Author

Michallet, Anne-Sophie, primary, Letestu, Rémi, additional, Le Garff-Tavernier, Magali, additional, Aanaei, Carmen, additional, Ticchioni, Michel, additional, Dilhuydy, Marie-Sarah, additional, Morisset, Stephane, additional, Rouille, Valérie, additional, Mahé, Béatrice, additional, Laribi, Kamel, additional, Villemagne, Bruno, additional, Ferrant, Emmanuelle, additional, Tournilhac, Olivier, additional, Delmer, Alain, additional, Portois, Christelle, additional, Molina, Lysiane, additional, Leblond, Véronique, additional, Tomowiak, Cécile, additional, de Guibert, Sophie, additional, Orsini, Frederique, additional, Banos, Anne, additional, Carassou, Philippe, additional, Cartron, Guillaume, additional, Fornecker, Luc Mathieu, additional, Ysebaert, Loic, additional, Dartigeas, Caroline, additional, Truchan, Margot, additional, Vilque, Jean-Pierre, additional, Aurran Schleinitz, Therese, additional, Florence, Cymbalista, additional, Leprêtre, Stéphane, additional, Lévy, Vincent, additional, Nguyen Khac, Florence, additional, and Feugier, Pierre, additional

Published
2022
Full Text
View/download PDF

18. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Author

Quinquenel, Anne, primary, Letestu, Rémi, additional, Le Garff-Tavernier, Magali, additional, Subtil, Fabien, additional, Aurran-Schleinitz, Therese, additional, Laribi, Kamel, additional, Cymbalista, Florence, additional, Levy, Vincent, additional, Simon, Laurence, additional, Roos-Weil, Damien, additional, Leblond, Véronique, additional, Dilhuydy, Marie-Sarah, additional, Dartigeas, Caroline, additional, Tomowiak, Cecile, additional, Guieze, Romain, additional, Tournilhac, Olivier, additional, Ferrant, Emmanuelle, additional, de Guibert, Sophie, additional, Feugier, Pierre, additional, Merabet, Fatiha, additional, Lepretre, Stephane, additional, Carassou, Philippe, additional, Gay, Julie, additional, Hivert, Bénédicte, additional, Fornecker, Luc Mathieu, additional, Dupuis, Jehan, additional, Molina, Lysiane, additional, Villemagne, Bruno, additional, Cartron, Guillaume, additional, Drenou, Bernard, additional, Mahé, Béatrice, additional, Benbrahim, Omar, additional, Cahu, Xavier, additional, Portois, Christelle, additional, Ysebaert, Loic, additional, Nguyen Khac, Florence, additional, Rouille, Valérie, additional, Delmer, Alain, additional, and Michallet, Anne-Sophie, additional

Published
2022
Full Text
View/download PDF

21. Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPM1 and CEBPA without FLT3-ITD

Author

Labouré, Gaëlle, Dulucq, Stéphanie, Labopin, Myriam, Tabrizi, Reza, Guérin, Estelle, Pigneux, Arnaud, Lafarge, Xavier, Leguay, Thibaut, Bouabdallah, Krimo, Dilhuydy, Marie-Sarah, Duclos, Cédric, Lascaux, Axelle, Marit, Gérald, Mahon, François-Xavier, Boiron, Jean-Michel, Milpied, Noël, and Vigouroux, Stéphane

Published
2012
Full Text
View/download PDF

23. Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion.

Author

Saos-Patrinos, Corentin Le, Loizon, Séverine, Zouine, Atika, Turpin, Delphine, Dilhuydy, Marie-Sarah, Blanco, Patrick, Sisirak, Vanja, Forcade, Edouard, and Duluc, Dorothée

Subjects
T helper cells, CHRONIC lymphocytic leukemia, B cells, BONE marrow cells, CHRONIC leukemia, T cells
Abstract

Chronic lymphocytic leukemia (CLL) is characterized by an expansion of mature B cells in the bone marrow, peripheral lymphoid organs, and blood. CD4 T helper (Th) lymphocytes significantly contribute to the physiopathology of CLL, but the subset(s) of Th cell involved in CLL pathogenesis is (are) still under debate. In this study, we performed flow cytometry analysis of the circulatory T cells of untreated CLL patients and observed an increase in follicular helper T cells (Tfh), which is a subset of T cells specialized in B cell help. Elevated numbers of Tfh cells correlated with disease severity as measured by the Binet staging system. Tfh from CLL patients were activated and skewed toward a Th1 profile as evidenced by their PD-1+IL-21+IFNγ+ phenotype and their CXCR3+CCR6− chemokine receptor profile. Tfh efficiently enhanced B-CLL survival and proliferation through IL-21 but independently of IFNγ. Finally, we observed an inverse correlation between the Tfh1 and IgA and IgG serum levels in patients, suggesting a role for this Tfh subset in the immune dysfunction associated with CLL. Altogether, our data highlight an impairment in circulatory Tfh subsets in CLL patients and their critical role in CLL physiopathology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Author

Doublet, Charlotte, primary, Dilhuydy, Marie-Sarah, additional, Ferrant, Emmanuelle, additional, Feugier, Pierre, additional, Fayault, Alexandra, additional, Robert, Philippine, additional, Lepretre, Stephane, additional, Delmer, Alain, additional, Tomowiak, Cécile, additional, Guieze, Romain, additional, Laribi, Kamel, additional, Vignon, Marguerite, additional, Clavert, Aline, additional, Bijou, Fontanet, additional, Re, Daniel, additional, Lara, Diane, additional, Merabet, Fatiha, additional, Tchernonog, Emmanuelle, additional, Dartigeas, Caroline, additional, Michallet, Anne-Sophie, additional, and Quinquenel, Anne, additional

Published
2021
Full Text
View/download PDF

27. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Author

Michallet, Anne-Sophie, primary, Quinquenel, Anne, additional, Letestu, Remi, additional, Le Garff-Tavernier, Magali, additional, Subtil, Fabien, additional, Elsensohn, Mad-Helenie, additional, Aurran, Therese, additional, Laribi, Kamel, additional, Cymbalista, Florence, additional, Levy, Vincent, additional, Simon, Laurence, additional, Roos-Weil, Damien, additional, Leblond, Veronique, additional, Dilhuydy, Marie-Sarah, additional, Tomowiak, Cécile, additional, Dartigeas, Caroline, additional, Guieze, Romain, additional, Tournilhac, Olivier, additional, Ferrant, Emmanuelle, additional, de Guibert, Sophie, additional, Feugier, Pierre, additional, Merabet, Fatiha, additional, Leprêtre, Stéphane, additional, Carassou, Philippe, additional, Gay, Julie, additional, Hivert, Bénédicte, additional, Fornecker, Luc Mathieu, additional, Dupuis, Jehan, additional, Molina, Lysiane, additional, Villemagne, Bruno, additional, Cartron, Guillaume, additional, Drenou, Bernard, additional, Mahé, Béatrice, additional, Benbrahim, Omar, additional, Cahu, Xavier, additional, Portois, Christelle, additional, Ysebaert, Loic, additional, Nguyen-Khac, Florence, additional, Rouille, Valérie, additional, and Delmer, Alain, additional

Published
2021
Full Text
View/download PDF

28. A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Author

Michallet, Anne-Sophie, Letestu, Rémi, Le Garff-Tavernier, Magali, Aanei, Carmen, Ticchioni, Michel, Dilhuydy, Marie-Sarah, Subtil, Fabien, Rouille, Valerie, Mahe, Beatrice, Laribi, Kamel, Villemagne, Bruno, Salles, Gilles, Tournilhac, Olivier, Delmer, Alain, Portois, Christelle, Pegourie, Brigitte, Leblond, Veronique, Tomowiak, Cecile, De Guibert, Sophie, Orsini Piocelle, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc-Matthieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan-Graczyk, Malgorzata, Vilque, Jean-Pierre, Aurran, Thérèse, Cymbalista, Florence, Lepretre, Stéphane, Levy, Vincent, Nguyen-Khac, Florence, and Feugier, Pierre

Published
2021
Full Text
View/download PDF

29. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

Author

Fornecker, Luc-Matthieu, Aurran-Schleinitz, Thérèse, Michallet, Anne-Sophie, Cazin, Bruno, Guieze, Romain, Dilhuydy, Marie-Sarah, Zini, Jean-Marc, Tomowiak, Cécile, Lepretre, Stéphane, Cymbalista, Florence, Brion, Annie, Feugier, Pierre, Delmer, Alain, Leblond, Véronique, and Ysebaert, Loïc

Published
2015
Full Text
View/download PDF

31. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )

Author

Lazarian, Grégory, primary, Munger, Michaël, additional, Quinquenel, Anne, additional, Dilhuydy, Marie‐Sarah, additional, Veronese, Lauren, additional, Luque Paz, Damien, additional, Guièze, Romain, additional, Ledoux‐Pilon, Albane, additional, Paillassa, Jérôme, additional, Merabet, Fatiha, additional, Vial, Jean‐Philippe, additional, Bidet, Audrey, additional, Waultier Rascalou, Agathe, additional, Broseus, Julien, additional, Roos‐Weil, Damien, additional, Lavaud, Anne, additional, Molina, Lysiane, additional, Laribi, Kamel, additional, Hivert, Bénédicte, additional, Friedrich, Chloé, additional, Carpentier, Benjamin, additional, Ysebaert, Loïc, additional, Van Den Neste, Eric, additional, Willems, Lise, additional, Corby, Anne, additional, Poulain, Stéphanie, additional, Eclache, Virginie, additional, Maubec, Eve, additional, Martin, Antoine, additional, Feugier, Pierre, additional, Delmer, Alain, additional, Baran‐Marszak, Fanny, additional, Leprêtre, Stéphane, additional, and Cymbalista, Florence, additional

Published
2021
Full Text
View/download PDF

32. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).

Author

UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Lazarian, Grégory, Munger, Michaël, Quinquenel, Anne, Dilhuydy, Marie-Sarah, Veronese, Lauren, Luque Paz, Damien, Guièze, Romain, Ledoux-Pilon, Albane, Paillassa, Jérôme, Merabet, Fatiha, Vial, Jean-Philippe, Bidet, Audrey, Waultier Rascalou, Agathe, Broseus, Julien, Roos-Weil, Damien, Lavaud, Anne, Molina, Lysiane, Laribi, Kamel, Hivert, Bénédicte, Friedrich, Chloé, Carpentier, Benjamin, Ysebaert, Loïc, Van Den Neste, Eric, Willems, Lise, Corby, Anne, Poulain, Stéphanie, Eclache, Virginie, Maubec, Eve, Martin, Antoine, Feugier, Pierre, Delmer, Alain, Baran-Marszak, Fanny, Leprêtre, Stéphane, Cymbalista, Florence, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Lazarian, Grégory, Munger, Michaël, Quinquenel, Anne, Dilhuydy, Marie-Sarah, Veronese, Lauren, Luque Paz, Damien, Guièze, Romain, Ledoux-Pilon, Albane, Paillassa, Jérôme, Merabet, Fatiha, Vial, Jean-Philippe, Bidet, Audrey, Waultier Rascalou, Agathe, Broseus, Julien, Roos-Weil, Damien, Lavaud, Anne, Molina, Lysiane, Laribi, Kamel, Hivert, Bénédicte, Friedrich, Chloé, Carpentier, Benjamin, Ysebaert, Loïc, Van Den Neste, Eric, Willems, Lise, Corby, Anne, Poulain, Stéphanie, Eclache, Virginie, Maubec, Eve, Martin, Antoine, Feugier, Pierre, Delmer, Alain, Baran-Marszak, Fanny, Leprêtre, Stéphane, and Cymbalista, Florence

Abstract

TO THE EDITOR : Patients with chronic lymphocytic leukemia (CLL) exhibit a variety of skin lesions including mostly non-specific cutaneous manifestations (such as cutaneous infections or exaggerated reactions to insect bite) and secondary cutaneous malignancies, as patients are at high risk of developing basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Specific cutaneous infiltration by neoplastic B lymphocytes with clinically identifiable skin lesions, also called leukemia cutis (LC), is more uncommon and has seldom been reported in chronic lymphocytic leukemia. [...]

Published
2021

34. Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Author

Michallet, Anne-Sophie, Quinquenel, Anne, Letestu, Remi, Magali, Tavernier, Morisset, Stéphane, Aurran, Therese, Laribi, Kamel, Cymbalista, Florence, Levy, Vincent, Simon, Laurence, Roos Weil, Damien, Leblond, Veronique, Dilhuydy, Marie Sarah, Tomowiak, Cecile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, De Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Lepretre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Benedicte, Fornecker, Luc Matthieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Mahé, Béatrice, Benbrahim, Omar, Cahu, Xavier, Portois, Christelle, Ysebaert, Loic, Nguyen Khac, Florence, Rouillé, Valerie, and Delmer, Alain Jacques

Published
2023
Full Text
View/download PDF

35. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Author

Goede, Valentin, Fischer, Kirsten, Busch, Raymonde, Engelke, Anja, Eichhorst, Barbara, Wendtner, Clemens M., Chagorova, Tatiana, de la Serna, Javier, Dilhuydy, Marie-Sarah, Illmer, Thomas, Opat, Stephen, Owen, Carolyn J., Samoylova, Olga, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Döhner, Hartmut, Langerak, Anton W., Ritgen, Matthias, Kneba, Michael, Asikanius, Elina, Humphrey, Kathryn, Wenger, Michael, and Hallek, Michael

Published
2014
Full Text
View/download PDF

37. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
0301 basic medicine, Male, Cancer Research, Neoplasm, Residual, MESH: Immunotherapy, Chronic lymphocytic leukemia, Gastroenterology, MESH: Clinical Trials, Phase III as Topic, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Aged, education.field_of_study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Prognosis, 3. Good health, Fludarabine, Survival Rate, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Vidarabine, MESH: Bone Marrow, Female, MESH: Rituximab, Immunotherapy, Rituximab, MESH: Clinical Trials, Phase II as Topic, Vidarabine, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Chemoimmunotherapy, Internal medicine, medicine, Humans, education, Survival rate, MESH: Neoplasm, Residual, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Retrospective Studies, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Male, body regions, 030104 developmental biology, Clinical Trials, Phase III as Topic, Bone marrow, business, MESH: Female, Follow-Up Studies
Abstract

International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD

Published
2020
Full Text
View/download PDF

38. Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Author

Fraser, Graeme, Chanan-Khan, Asher, Demirkan, Faith, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy, Dilhuydy, Marie Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlosky, Miguel, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Balasubramanian, Sriram, Howes, Angela, Cramer, Paula, Fraser, Graeme, Chanan-Khan, Asher, Demirkan, Faith, Silva, Rodrigo Santucci, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy, Dilhuydy, Marie Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlosky, Miguel, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Balasubramanian, Sriram, Howes, Angela, and Cramer, Paula

Published
2020

39. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Author

Fraser, Graeme A. M., Chanan-Khan, Asher, Demirkan, Fatih, Santucci Silva, Rodrigo, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L., Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlovsky, Miguel A., Goy, Andre, Mato, Anthony, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Schuier, Natasha, Balasubramanian, Sriram, Howes, Angela, Cramer, Paula, Fraser, Graeme A. M., Chanan-Khan, Asher, Demirkan, Fatih, Santucci Silva, Rodrigo, Grosicki, Sebastian, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L., Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Pavlovsky, Miguel A., Goy, Andre, Mato, Anthony, Hallek, Michael, Salman, Mariya, Tamegnon, Monelle, Sun, Steven, Connor, Anne, Nottage, Kerri, Schuier, Natasha, Balasubramanian, Sriram, Howes, Angela, and Cramer, Paula

Abstract

We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion 17p (n = 578) were randomized 1:1 to 420 mg daily ibrutinib or placebo plus <= 6 cycles of bendamustine plus rituximab (BR), followed by ibrutinib or placebo alone. Median follow-up was 63.7 months. Median investigator-assessed progression-free survival was longer with ibrutinib plus BR (65.1 months) than placebo plus BR (14.3 months; hazard ratio [HR] 0.229 [95% confidence interval (CI) 0.183-0.286];p < .0001). Despite crossover of 63.3% of patients from the placebo plus BR arm to ibrutinib treatment upon disease progression, ibrutinib plus BR versus placebo plus BR demonstrated an overall survival benefit (HR 0.611 [95% CI 0.455-0.822];p = .0010; median not reached in either arm). Long-term follow-up data confirm the survival benefit of ibrutinib plus BR over BR alone. Safety profiles were consistent with those known for ibrutinib and BR.

Published
2020

40. The 10-years EBMT Landscape of Allogeneic Hematopoietic Cell Transplantation (Allohct) for Chronic Lymphocytic Leukemia

Author

Tournilhac, Olivier, van Gelder, Michel, Dreger, Peter, Bornhaeuser, Martin, Platzbecker, Uwe, Scheid, Christof, Beelen, Dietrich, Jindra, Pavel, Cornelissen, Jan J., Sengeloev, Henrik, Nguyen, Stephanie, Mayer, Jiri, Stelljes, Matthias, Dilhuydy, Marie-Sarah, Griskevicius, Laimonas, Vitek, Antonin, Nikolousis, Manos, Kroeger, Nicolaus, Hellmann, Andrzej, Santarone, Stella, Zinger, Nienke, Hayden, Patrick, Yakoub-Agha, Ibrahim, Tournilhac, Olivier, van Gelder, Michel, Dreger, Peter, Bornhaeuser, Martin, Platzbecker, Uwe, Scheid, Christof, Beelen, Dietrich, Jindra, Pavel, Cornelissen, Jan J., Sengeloev, Henrik, Nguyen, Stephanie, Mayer, Jiri, Stelljes, Matthias, Dilhuydy, Marie-Sarah, Griskevicius, Laimonas, Vitek, Antonin, Nikolousis, Manos, Kroeger, Nicolaus, Hellmann, Andrzej, Santarone, Stella, Zinger, Nienke, Hayden, Patrick, and Yakoub-Agha, Ibrahim

Published
2020

41. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Author

Quinquenel, Anne, Fornecker, Luc-Matthieu, Letestu, Rémi, Ysebaert, Loïc, Fleury, Carole, Lazarian, Grégory, Dilhuydy, Marie-Sarah, Nollet, Delphine, Guieze, Romain, Feugier, Pierre, Roos-Weil, Damien, Willems, Lise, Michallet, Anne-Sophie, Delmer, Alain, Hormigos, Katia, Levy, Vincent, Cymbalista, Florence, and Baran-Marszak, Fanny

Published
2019
Full Text
View/download PDF

42. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)

Author

Quinquenel, Anne, primary, Aurran-Schleinitz, Thérèse, additional, Clavert, Aline, additional, Cymbalista, Florence, additional, Dartigeas, Caroline, additional, Davi, Frédéric, additional, de Guibert, Sophie, additional, Delmer, Alain, additional, Dilhuydy, Marie-Sarah, additional, Feugier, Pierre, additional, Fornecker, Luc-Matthieu, additional, Ghez, David, additional, Guieze, Romain, additional, Laribi, Kamel, additional, Leblond, Véronique, additional, Leprêtre, Stéphane, additional, Letestu, Rémi, additional, Lévy, Vincent, additional, Nguyen-Khac, Florence, additional, Michallet, Anne-Sophie, additional, Tomowiak, Cécile, additional, Tournilhac, Olivier, additional, Ysebaert, Loïc, additional, and Troussard, Xavier, additional

Published
2020
Full Text
View/download PDF

44. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Author

Fraser, Graeme A.M., primary, Chanan-Khan, Asher, additional, Demirkan, Fatih, additional, Santucci Silva, Rodrigo, additional, Grosicki, Sebastian, additional, Janssens, Ann, additional, Mayer, Jiri, additional, Bartlett, Nancy L., additional, Dilhuydy, Marie-Sarah, additional, Loscertales, Javier, additional, Avigdor, Abraham, additional, Rule, Simon, additional, Samoilova, Olga, additional, Pavlovsky, Miguel A., additional, Goy, Andre, additional, Mato, Anthony, additional, Hallek, Michael, additional, Salman, Mariya, additional, Tamegnon, Monelle, additional, Sun, Steven, additional, Connor, Anne, additional, Nottage, Kerri, additional, Schuier, Natasha, additional, Balasubramanian, Sriram, additional, Howes, Angela, additional, and Cramer, Paula, additional

Published
2020
Full Text
View/download PDF

45. Vinblastine for elderly and frail patients with Hodgkin lymphoma

Author

Meynard, Lucie, primary, Galtier, Jean, additional, Favre, Simon, additional, Debus, Lucile, additional, Lascaux, Axelle, additional, Dilhuydy, Marie-Sarah, additional, Gros, François-Xavier, additional, Sauvezie, Mathieu, additional, Milpied, Noel, additional, Bouabdallah, Krimo, additional, and Dimicoli, Sophie, additional

Published
2020
Full Text
View/download PDF

48. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

Author

Brown, Jennifer R., Moslehi, Javid, Ewer, Michael S., O'Brien, Susan M., Ghia, Paolo, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Coutre, Steven E., Dilhuydy, Marie-Sarah, Cramer, Paula, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Treon, Steven, Liu, Emily Y., Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay, Mahler, Michelle, Yang, Huiying, Graef, Thorsten, Burger, Jan A., Brown, Jennifer R., Moslehi, Javid, Ewer, Michael S., O'Brien, Susan M., Ghia, Paolo, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Coutre, Steven E., Dilhuydy, Marie-Sarah, Cramer, Paula, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Treon, Steven, Liu, Emily Y., Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay, Mahler, Michelle, Yang, Huiying, Graef, Thorsten, and Burger, Jan A.

Abstract

Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B-cell malignancies. In ibrutinib clinical studies, low-grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We analysed the incidence of and risk factors for MH from 15 ibrutinib clinical studies (N = 1768), including 4 randomised controlled trials (RCTs). Rates of any-grade bleeding were similar for single-agent ibrutinib and ibrutinib combinations (39% and 40%). Low-grade bleeding was more common in ibrutinib-treated than comparator-treated patients (35% and 15%), and early low-grade bleeding was not associated with MH. The proportion of MH in RCTs was higher with ibrutinib than comparators (4.4% vs. 2.8%), but after adjusting for longer exposure with ibrutinib (median 13 months vs. 6 months), the incidence of MH was similar (3.2 vs. 3.1 per 1000 person-months). MH led to treatment discontinuation in 1% of all ibrutinib-treated patients. Use of anticoagulants and/or antiplatelets (AC/AP) during the study was common (similar to 50% of patients) and had an increased exposure-adjusted relative risk for MH in both the total ibrutinib-treated population (1.9; 95% confidence interval, 1.2-3.0) and RCT comparator-treated patients (2.4; 95% confidence interval, 1.0-5.6), indicating that ibrutinib may not alter the effect of AC/AP on the risk of MH in B-cell malignancies.

Published
2019

49. Actualités dans la leucémie lymphoïde chronique Quelques temps forts du congrès 2021de la Société française d'hématologie.

Author

Dilhuydy, Marie-Sarah and Quinquenel, Anne

Abstract

Résumé: Le congrès de la Société française d'hématologie, qui s'est tenu en septembre 2021, a été l'occasion, au cours de conférences scientifiques, de faire le point sur les données récentes concernant les principales classes thérapeutiques utilisées dans la leucémie lymphoïde chronique, à savoir les inhibiteurs de la tyrosine kinase de Bruton et les inhibiteurs de BCL2 (pour B-cell lymphoma 2). Des données très intéressantes concernant la vaccination anti-Sars-Cov-2 ont également été présentées lors des séances de communications orales. L'objectif de cet article est de faire la synthèse des différentes thématiques abordées concernant la leucémie lymphoïde chronique lors de ce congrès. The French Haematology Society Congress, held in September 2021, provided an opportunity to review recent data on the main therapeutic classes used in chronic lymphocytic leukaemia, namely BTK inhibitors and BCL2 inhibitors, during scientific conferences. Very interesting data on Sars-Cov-2 vaccination were also presented in the oral sessions. The aim of this article is to summarise the different topics discussed on chronic lymphocytic leukaemia at this congress. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Author

Michallet, Anne-Sophie, primary, Dilhuydy, Marie-Sarah, additional, Subtil, Fabien, additional, Rouille, Valérie, additional, Mahe, Beatrice, additional, Laribi, Kamel, additional, Villemagne, Bruno, additional, Salles, Gilles A., additional, Tournilhac, Olivier, additional, Delmer, Alain Jacques, additional, Portois, Christelle, additional, Pegourie, Brigitte, additional, Leblond, Veronique, additional, Tomowiak, Cecile, additional, de Guibert, Sophie, additional, Orsini, Frederique, additional, Banos, Anne, additional, Carassou, Philippe, additional, Cartron, Guillaume, additional, Fornecker, Luc Mathieu, additional, Ysebaert, Loic, additional, Dartigeas, Caroline, additional, Truchan, Margot, additional, Vilque, Jean Pierre, additional, Aurran, Thérèse, additional, Cymbalista, Florence, additional, Lepretre, Stephane, additional, Levy, Vincent, additional, Nguyen-Khac, Florence, additional, Le Garff-Tavernier, Magali, additional, Aanaei, Carmen, additional, Ticchioni, Michel, additional, Letestu, Remi, additional, and Feugier, Pierre, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results